Lobbying Update: $260,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed

$260,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to patient access to treatments Issues related to newborn screening for rare diseases Issues related to scientiﬁc innovation in healthcare such as gene therapies Issues related to artiﬁcial intelligence and data governance Tax issues related to research and development"

You can find more data on corporate lobbying on Quiver Quantitative.

SRPT Congressional Stock Trading

Members of Congress have traded $SRPT stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $SRPT stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 04/14.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

SRPT Insider Trading Activity

SRPT insiders have traded $SRPT stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $SRPT stock by insiders over the last 6 months:

CLAUDE NICAISE sold 2,491 shares for an estimated $248,203

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

SRPT Hedge Fund Activity

We have seen 206 institutional investors add shares of SRPT stock to their portfolio, and 250 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BANK OF NEW YORK MELLON CORP removed 1,354,401 shares (-63.1%) from their portfolio in Q1 2025, for an estimated $86,437,871
BLACKROCK, INC. removed 1,285,118 shares (-11.5%) from their portfolio in Q1 2025, for an estimated $82,016,230
MORGAN STANLEY added 980,467 shares (+98.9%) to their portfolio in Q1 2025, for an estimated $62,573,403
JANUS HENDERSON GROUP PLC removed 963,478 shares (-22.3%) from their portfolio in Q1 2025, for an estimated $61,489,165
ORBIMED ADVISORS LLC removed 963,400 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $61,484,188
DEEP TRACK CAPITAL, LP added 899,731 shares (+inf%) to their portfolio in Q1 2025, for an estimated $57,420,832
WELLINGTON MANAGEMENT GROUP LLP added 577,848 shares (+27.9%) to their portfolio in Q1 2025, for an estimated $36,878,259

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

SRPT Analyst Ratings

Wall Street analysts have issued reports on $SRPT in the last several months. We have seen 11 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Overweight" rating on 07/17/2025
Baird issued a "Outperform" rating on 07/17/2025
Needham issued a "Buy" rating on 07/17/2025
Wells Fargo issued a "Overweight" rating on 07/17/2025
HC Wainwright & Co. issued a "Sell" rating on 06/25/2025
Oppenheimer issued a "Outperform" rating on 06/20/2025
Mizuho issued a "Outperform" rating on 06/18/2025

To track analyst ratings and price targets for SRPT, check out Quiver Quantitative's $SRPT forecast page.

SRPT Price Targets

Multiple analysts have issued price targets for $SRPT recently. We have seen 20 analysts offer price targets for $SRPT in the last 6 months, with a median target of $40.0.

Here are some recent targets:

Gena Wang from Barclays set a target price of $32.0 on 07/17/2025
Brian Skorney from Baird set a target price of $35.0 on 07/17/2025
Yanan Zhu from Wells Fargo set a target price of $65.0 on 07/17/2025
Brian Abrahams from RBC Capital set a target price of $23.0 on 07/17/2025
Gil Blum from Needham set a target price of $50.0 on 07/17/2025
Anupam Rama from JP Morgan set a target price of $28.0 on 07/10/2025
Mitchell Kapoor from HC Wainwright & Co. set a target price of $10.0 on 06/25/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.